PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY (PTCA) BALLOON CATHETER MARKET ANALYSIS

Percutaneous transluminal coronary angioplasty (PTCA) also called percutaneous coronary intervention (PCI) is a minimally invasive procedure to open blocked or stenosed coronary arteries allowing unobstructed blood flow to the myocardium. The blockage occurs because of lipid-rich plaque within the arteries, diminishing blood flow to the myocardium. The accumulation of lipid-rich plaque in the arteries is known as atherosclerosis, and when atherosclerosis affects the coronary arteries, the disorder is known as coronary artery disease.

A PTCA catheter is a device that operates on the principle of hydraulic pressurization applied through an inflatable balloon attached to the distal end. A PTCA balloon catheter has a single or double lumen shaft. The catheter features a balloon of appropriate compliance for clinical application, constructed from a polymer.

The percutaneous transluminal coronary angioplasty (PTCA) balloon catheter market is estimated to be valued at US$ 2.2 Billion in 2022 and is expected to exhibit a CAGR of 8 % over the forecast period (2022-2030)

Figure 1. Global Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheter Market Value (US$ Mn), By Region, 2022

To learn more about this report, request sample copy

Increasing cardiovascular disease epidemiology worldwide is expected to boost the percutaneous transluminal coronary angioplasty (PTCA) market growth over the forecast period.

For instance, according to the data published in the Centers for Disease Control and Prevention in 2020, in the year 2020, about 20.1 million adults age 20 and older had cardiovascular diseases (about 7.2%), and about 2 in 10 deaths from cardiovascular diseases happened in adults less than 65 years old in U.S.

Figure 2. Global Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheter Market Share (%), By Product Type, 2022

To learn more about this report, request sample copy

Increasing product launches and approvals are expected to drive the growth of the percutaneous transluminal coronary angioplasty (PTCA) balloon catheter market over the forecast period.

For instance, in July 2021, MedAlliance, a medical technology company headquartered in Switzerland, had launched ORIGIN NC, two high-performance balloons for vessel preparation. ORIGIN SC is a semi-compliant (SC) PTCA with a very low crossing profile. Its sizes include 1.00 mm, 1.25 mm, 1.50 mm, and 1.75 mm balloon diameter to treat very small vessels and complex cases.

ORIGIN NC is a non-compliant (NC) PTCA balloon, combining high-pressure tolerance and controlled compliance with an optimal crossing profile for challenging cases.

Moreover, in August 2018, S3V Vascular Technologies Private Limited, a medical devices manufacturing company, launched Nextgen PTCA (Percutaneous Transluminal Coronary Angioplasty) Balloon Catheters.

Global Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheter Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 a pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 583,038,110 cases of coronavirus disease (COVID-19) were reported till August 9, 2022, across the globe.

Cardiac surgery patients have an increased risk of complications from COVID-19 and require vital finite resources such as intensive care beds, and same needed by the covid-19 patient, thus admission of cardiac patient was reduced during the peak of covid-19 spread. Moreover, only emergencies such as acute aortic dissections were treated.

Moreover, according to an article published by CTV new in September 2021, Hamilton General Hospital had to cancel all cardiac surgeries for an entire day as it scramble to free up resources to care for COVID-19 patients in its intensive care unit.         

Global Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheter Market Restraint

Increasing product recalls are expected to hinder the growth of the percutaneous transluminal coronary angioplasty (PTCA) balloon catheter market over the forecast period. For instance, in February 2020, Abbott, a medical device and healthcare company, had voluntarily recalled specific lots of two types of its coronary angioplasty catheters – NC Trek RX Coronary Dilatation Catheter and NC Traveler Coronary Dilatation Catheter, as the balloons from the impacted lots may not deflect as intended, and the U.S Food and Drug Administration has classified this as Class I recall.

Key Players

Major players operating in the global percutaneous transluminal coronary angioplasty (PTCA) balloon catheter market include Cook Group, Medtronic Plc., Becton, Dickinson and Company, Abbott, Koninklijke Philips N.V., ENDOCOR GmbH, Cardinal Health, NIPRO, Terumo Corporation, Boston Scientific Corporation, Surmodics, Inc., Teleflex Incorporated, BIOTRONIK SE & Co. KG, Biomerics, Shockwave Medical Inc., Microport Scientific Corporation, Nordson Corporation, and S3V Vascular Technologies Pvt. Ltd.